Algorae Pharmaceuticals (ASX:1AI) Shareholder Yield % : -0.91% (As of Dec. 2025)


What is Algorae Pharmaceuticals Shareholder Yield %?

Algorae Pharmaceuticals ASX:1AI Shareholder Yield % is -0.91% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 1,301 Biotechnology companies, Algorae Pharmaceuticals ranks better than 52.73% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Algorae Pharmaceuticals's Shareholder Yield % was -0.91%.


Algorae Pharmaceuticals  (ASX:1AI) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Algorae Pharmaceuticals Shareholder Yield % Related Terms


Algorae Pharmaceuticals Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Algorae Pharmaceuticals's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algorae Pharmaceuticals Shareholder Yield % Chart

Algorae Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 -27.78 -9.18 -3.34 0.00

Algorae Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.09 -3.34 -0.41 0.00 -0.86

ASX:1AI vs VRTX, REGN, ALNY: Shareholder Yield % Comparison

For the Biotechnology subindustry, Algorae Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Shareholder Yield % falls into.



Algorae Pharmaceuticals Shareholder Yield % Calculation

Algorae Pharmaceuticals's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-0.86 %+0 %
=-0.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -0.91% mean?
Algorae Pharmaceuticals (ASX:1AI) has a Shareholder Yield % of -0.91% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Algorae Pharmaceuticals and its competitors. According to the industry distribution chart, Algorae Pharmaceuticals ranks #615 out of 1301 companies in the Biotechnology industry, placing it in the top 47.3%.
Is Algorae Pharmaceuticals' Shareholder Yield % too high?
Algorae Pharmaceuticals' current Shareholder Yield % is -0.91%. Based on the distribution chart, Algorae Pharmaceuticals ranks #615 out of 1301 companies in the Biotechnology industry, which is above the industry midpoint.
How does Algorae Pharmaceuticals' Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #615 out of 1301 companies for Shareholder Yield %. This puts Algorae Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Algorae Pharmaceuticals and its competitors. Algorae Pharmaceuticals's current Shareholder Yield % is -0.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Shareholder Yield % of -0.91%. The current Shareholder Yield % is -0.91%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Shareholder Yield % is -0.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Algorae Pharmaceuticals Business Description

Other Exchanges LVCLF:USALHI0:Germany
Address 525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.